Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Pharma To Invest More On NCD Partnerships Over Next Decade – IFPMA Report

This article was originally published in PharmAsia News

Executive Summary

Although Big Pharma is investing more in partnerships related to non-communicable diseases such as cancer and diabetes, gaps remain in tech transfer activities and local solutions in developing nations where NCDs are on the rise.

You may also be interested in...

Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases

MUMBAI - Following the Indian government's heightened concerns over a sharply increased prevalence rate of non-communicable diseases such as diabetes and cancer, Eli Lilly & Co. has allocated $8-9 million to analyze the disease burden in India and devise intervention strategies based on the data

GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives

TOKYO - GlaxoSmithKline is making rounds to draw big pharma partners to its patent pool and open laboratory for neglected disease research, but questions linger over what will happen if precompetitive collaboration produces technology or compounds that have use outside of the world's poorest countries

China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?

Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts